Happening soon: Free Gift with Riccar Purchase on the Abington Patch calendar ...

Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also ...

Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- ...

These results provide longer-term evidence that Scemblix demonstrated increasingly superior molecular responses at week 144 compared with established tyrosine kinase inhibitors (TKIs), strengthening ...

A Limerick councillor has called on Limerick City and County Council to formally support survivors of the former Bessborough ...

Several insiders have alleged that the actor clashed with his co-stars and the production crew while filming the hit ...

The Mitchell Board of Education will get a look at the preliminary Mitchell Technical College and Mitchell School District ...

A new book reports growing interest in bespoke rituals. But when God’s not in the equation, rituals lose their potency.

In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at the American Academy of Neurology (AAN) Annual Meeting 2026.

AICPA system and organization controls (SOC) reporting has become a cornerstone of trust in today’s technology-driven market, with SOC 2 reports playing a critical role in third-party risk management.

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in ...

Seven days ago, the US-Iran ceasefire was holding but negotiations seemed stalled, or inching forward at best. Then, Donald Trump and the US launched Project Freedom It has been a week of dizzying, ...